Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)
該当なし
実施中(募集終了)
NCT01696994
| 対象疾患 | Ovarian Carcinoma, Ovarian Germ Cell Tumor |
|---|
| 相 | 該当なし |
|---|
| スポンサー | National Cancer Institute (NCI) |
|---|
| ステータス | 実施中(募集終了) |
|---|
| 参加者数 | 78,216 名 |
|---|
| 介入(薬剤) | Laboratory Biomarker Analysis, Screening Questionnaire Administration, Ultrasound Imaging |
|---|
| 開始日 | 1993年11月16日 |
|---|
| 完了日 | 2012年5月21日 |
|---|
| 結果公開日 | 2014年12月12日 |
|---|
概要
This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).
Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years. · Participants
| Control | 100 Participants |
|---|
| Ovarian Screening | 188 Participants |
|---|
Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)
Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years. · Deaths per 10,000 PY
| Control | 2.6 Deaths per 10,000 PY |
|---|
| Ovarian Screening | 3.1 Deaths per 10,000 PY |
|---|
| Hazard Ratio (HR) | 1.18 (95% CI .91–1.54) |
BENITIONS で見る
ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。